UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

The New England journal of medicine, 2010-04, Vol.362 (17), p.1563-1574

2010

Volltextzugriff (PDF)

Fibrates for primary prevention of cardiovascular disease events

Cochrane database of systematic reviews, 2016-11, Vol.11 (3), p.CD009753

2016

Volltextzugriff (PDF)

Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration

Molecular pharmaceutics, 2019-05, Vol.16 (5), p.1958-1970

2019

Volltextzugriff (PDF)

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme

Clinical drug investigation, 2008-01, Vol.28 (10), p.625-634

2008

Volltextzugriff (PDF)

Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Alcoholism, clinical and experimental research, 2015-01, Vol.39 (1), p.136-145

2015

Volltextzugriff (PDF)

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Journal of clinical lipidology, 2018-01, Vol.12 (1), p.173-184

2018

Volltextzugriff (PDF)

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Atherosclerosis, 2016-06, Vol.249, p.36-43

2016

Volltextzugriff (PDF)

Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy

American journal of physiology. Renal physiology, 2017-02, Vol.312 (2), p.F323-F334

2017

Volltextzugriff (PDF)

Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress

Oncogene, 2024-01, Vol.43 (2), p.136-150

2024

Volltextzugriff (PDF)

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice

Investigative ophthalmology & visual science, 2022-06, Vol.63 (6), p.12-12

2022

Volltextzugriff (PDF)

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Cochrane database of systematic reviews, 2018-11, Vol.11 (11), p.CD012502

2018

Volltextzugriff (PDF)

A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate

European journal of pharmacology, 2023-01, Vol.938, p.175428-175428, Article 175428

2023

Volltextzugriff (PDF)

Fibrates for secondary prevention of cardiovascular disease and stroke

Cochrane database of systematic reviews, 2015-10, Vol.2018 (10), p.CD009580

2015

Volltextzugriff (PDF)

Fenofibrate for Treating Diabetic Eye Disease

Diabetes (New York, N.Y.), 2023-07, Vol.72 (7), p.838-840

2023

Volltextzugriff (PDF)

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study

Ophthalmology (Rochester, Minn.), 2014-12, Vol.121 (12), p.2443

2014

Volltextzugriff (PDF)

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality

Atherosclerosis, 2021-12, Vol.339, p.55-56

2021

Volltextzugriff (PDF)

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

The New England journal of medicine, 2010-07, Vol.363 (3), p.233-244

2010

Volltextzugriff (PDF)

Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice

Molecular and cellular endocrinology, 2015-02, Vol.402, p.86-94

2015

Volltextzugriff (PDF)

Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-07, Vol.72 (7), p.932-946

2023

Volltextzugriff (PDF)

Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Diabetes (New York, N.Y.), 2023-07, Vol.72 (7), p.958-972

2023

Volltextzugriff (PDF)

Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD

Diabetes care, 2022-07, Vol.45 (7), p.1584-1591

2022

Volltextzugriff (PDF)

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form

Molecular pharmaceutics, 2021-09, Vol.18 (9), p.3588-3600

2021

Volltextzugriff (PDF)

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Expert opinion on pharmacotherapy, 2014-03, Vol.15 (4), p.493-503

2014

Volltextzugriff (PDF)

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Cochrane database of systematic reviews, 2013-12 (12), p.CD008623-CD008623

2013

Volltextzugriff (PDF)

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

The Lancet (British edition), 2005-11, Vol.366 (9500), p.1849-1861

2005

Volltextzugriff (PDF)

1 – 25 von 1.278

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.155)

Publikationsform

Sprache

14 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Fenofibrate - Therapeutic Use
(1.140)
Humans
(1.103)
Science & Technology
(979)
Life Sciences & Biomedicine
(962)
Hypolipidemic Agents - Therapeutic Use
(787)
Male
(732)
Female
(579)
Middle Aged
(539)
Fenofibrate
(527)
Adult
(360)
Biological And Medical Sciences
(328)
Medical Sciences
(323)
Aged
(316)
Fenofibrate - Pharmacology
(268)
Animals
(253)
Triglycerides - Blood
(238)
Cardiovascular System & Cardiology
(237)
Pharmacology & Pharmacy
(222)
Treatment Outcome
(212)
Drug Therapy, Combination
(201)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

Fibrates for primary prevention of cardiovascular disease events

Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme

Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy

Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate

Fibrates for secondary prevention of cardiovascular disease and stroke

Fenofibrate for Treating Diabetic Eye Disease

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice

Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Aktive Filter

Suchergebnisse filtern